PDPHF Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth (+112%) demonstrates the company is gaining commercial traction or advancing clinical assets that generate higher income. Over the next 2–6 months, durable top-line expansion can support scale economics, improve negotiating leverage with partners, and justify continued R&D investment if growth persists.
Manageable LeverageA debt-to-equity near 0.30 indicates the company is not highly leveraged relative to peers, lowering short-term solvency risk. This structural capital mix gives management room to finance near-term clinical and commercial needs through non-debt routes and reduces bankruptcy risk while it pursues milestone-driven value creation.
Orphan-disease FocusConcentrating on orphan and rare indications provides structural advantages: regulatory incentives, accelerated pathways, pricing power, and smaller commercial footprints to serve. This niche strategy can sustain higher long-term margins per approved product and reduce direct competition versus broader indications.
Bears Say
Severe Cash BurnVery large negative operating and free cash flow indicate the company is consuming capital at a material rate. Over months this creates financing dependency and dilution risk, constrains discretionary R&D and commercialization spending, and limits ability to respond to setbacks without external financing.
Very Weak ProfitabilityA net margin near -592% and deeply negative operating results show the business is far from break-even. Such persistent unprofitability undermines self-funded growth, increases reliance on capital markets, and signals that current operations and cost structure are not yet scalable or sustainable in absence of transformative product approvals.
Equity Erosion & Negative ROEMaterial equity decline and ~-98% ROE reflect capital depletion from sustained losses. This erodes financial flexibility, heightens future dilution risk when raising funds, and can limit strategic options like partnerships or in‑licensing, making long-term execution and scaling more difficult without clear funding plans.
PDPHF FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Currently, no data Available
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is $321.48M.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 26 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Apr 29, 2026. The company reported -$0.025 earnings per share for the quarter, missing the consensus estimate of -$0.019 by -$0.005.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.02.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -$0.025 in its last earnings report, missing expectations of -$0.019. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in PDPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
PDPHF Stock 12 Month Forecast
Average Price Target
$2.36